Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis.

PubWeight™: 0.89‹?›

🔗 View Article (PMID 27070090)

Published in Oncotarget on May 31, 2016

Authors

Marta Anna Kowalik1, Giulia Guzzo2, Andrea Morandi3, Andrea Perra1, Silvia Menegon4, Ionica Masgras2, Elena Trevisan2, Maria Maddalena Angioni1, Francesca Fornari5, Luca Quagliata6, Giovanna Maria Ledda-Columbano1, Laura Gramantieri5, Luigi Terracciano6, Silvia Giordano4, Paola Chiarugi3, Andrea Rasola2, Amedeo Columbano1

Author Affiliations

1: Department of Biomedical Sciences, University of Cagliari, 09124, Cagliari, Italy.
2: Department of Biomedical Sciences, University of Padova, 35122, Padova, Italy.
3: Department of Experimental and Clinical Biomedical Sciences, University of Florence, Firenze and Tuscan Tumor Institute, 50134, Florence, Italy.
4: Department of Oncology, University of Torino School of Medicine, Candiolo Cancer Institute-FPO, IRCCS, 10060, Candiolo, Italy.
5: Azienda Ospedaliero-Universitaria Policlinico S. Orsola Malpighi, 40138, Bologna, Italy.
6: Molecular Pathology Division, Institute of Pathology, University Hospital of Basel, CH-4003, Basel, Switzerland.

Articles cited by this

Hallmarks of cancer: the next generation. Cell (2011) 140.01

Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82

On the origin of cancer cells. Science (1956) 49.55

Cancer cell metabolism: Warburg and beyond. Cell (2008) 11.80

Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell (2012) 9.88

MYC on the path to cancer. Cell (2012) 8.65

The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science (2010) 6.38

p53 and metabolism. Nat Rev Cancer (2009) 5.05

Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell (2012) 3.90

How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature (2012) 3.77

HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest (2013) 3.55

Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest (2013) 3.46

The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev (2013) 3.40

The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci (2014) 2.53

Rapid emergence of carcinogen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis. Am J Pathol (1977) 2.45

The Emerging Hallmarks of Cancer Metabolism. Cell Metab (2016) 2.32

Progenitor-derived hepatocellular carcinoma model in the rat. Hepatology (2010) 2.03

Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PLoS One (2008) 1.87

Oncometabolites: linking altered metabolism with cancer. J Clin Invest (2013) 1.78

The pentose phosphate pathway and cancer. Trends Biochem Sci (2014) 1.65

Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice. J Clin Invest (2008) 1.62

Nrf2, but not β-catenin, mutation represents an early event in rat hepatocarcinogenesis. Hepatology (2015) 1.60

Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J Clin Invest (2013) 1.42

Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis. Proc Natl Acad Sci U S A (2013) 1.37

The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase. Cell Metab (2013) 1.36

Defects in mitochondrial metabolism and cancer. Cancer Metab (2014) 1.24

The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta (2010) 1.22

Understanding the central role of citrate in the metabolism of cancer cells. Biochim Biophys Acta (2011) 1.13

Mitochondrial oxidative phosphorylation TRAP(1)ped in tumor cells. Trends Cell Biol (2014) 1.10

MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC). Hepatology (2013) 1.05

Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread. Oncotarget (2015) 0.97

Kinetics of phenotypic maturation of remodeling of hyperplastic nodules during liver carcinogenesis. Cancer Res (1982) 0.96

The multifaceted regulation and functions of PKM2 in tumor progression. Biochim Biophys Acta (2014) 0.95

TIGAR, TIGAR, burning bright. Cancer Metab (2014) 0.91

Myotonic dystrophy protein kinase (DMPK) prevents ROS-induced cell death by assembling a hexokinase II-Src complex on the mitochondrial surface. Cell Death Dis (2013) 0.90

Induction of the permeability transition pore in cells depleted of mitochondrial DNA. Biochim Biophys Acta (2012) 0.90

Inhibition of succinate dehydrogenase by the mitochondrial chaperone TRAP1 has anti-oxidant and anti-apoptotic effects on tumor cells. Oncotarget (2014) 0.86

Cytokeratin-19 positivity is acquired along cancer progression and does not predict cell origin in rat hepatocarcinogenesis. Oncotarget (2015) 0.84

The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival. J Hepatol (2015) 0.77